Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.42 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 7/20 | 0.41 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.39 |
| ▸ | JAK3 | P52333 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5543229 | 1.00 | USP30 (0.42) | USP30EGLN2PRKCQDPP4DPP7 | |
| SCHEMBL5543235 | 1.00 | USP30 (0.42) | USP30EGLN2PRKCQDPP4DPP7 | |
| SCHEMBL5549920 | 1.00 | USP30 (0.42) | USP30EGLN2PRKCQDPP4DPP7 | |
| SCHEMBL5545238 | 1.00 | USP30 (0.42) | USP30EGLN2PRKCQDPP4DPP7 | |
| SCHEMBL5549932 | 1.00 | USP30 (0.42) | USP30EGLN2PRKCQDPP4DPP7 | |
| SCHEMBL15739611 | 0.87 | EGLN2 (0.51) | USP30EGLN2DPP4DPP7DPP8 | |
| SCHEMBL27304307 | 0.78 | CHEK1 (0.57) | USP30EGLN2PRKCQDPP4DPP7 | |
| SCHEMBL27304051 | 0.77 | EGLN2 (0.43) | USP30EGLN2DPP4DPP7DPP8 | |
| SCHEMBL5548760 | 0.77 | DPP4 (0.42) | USP30DPP4DPP7DPP8CYP2D6 | |
| SCHEMBL5548764 | 0.77 | DPP4 (0.42) | USP30DPP4DPP7DPP8CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | claimed |
| US-7230002-B2 | Dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-06-12 | — | — | US | disclosed |
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | GLENMARK PHARMACEUTICALS LTD. (IN) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192324-A1 | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | DPP4, DPP3, DPP7 | USP30 896/4885EGLN2 1746/4885PRKCQ 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.